Fulcrum Therapeutics

Yahoo Finance • 19 days ago

Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock, pre-funded warrants

* Fulcrum Therapeutics (FULC [https://seekingalpha.com/symbol/FULC]) on Wednesday announced the pricing of its underwritten public offering of 11.85M shares of its common stock at a public offering price of $13.50 per share, and, in lieu... Full story

Yahoo Finance • 20 days ago

Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with geneticall... Full story

Yahoo Finance • 22 days ago

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at Week 6 (vs. 5.6% at Week 6 in the 12 mg coh... Full story

Yahoo Finance • 23 days ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined ra... Full story

Yahoo Finance • 2 months ago

Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: HSBC upgraded Caterpillar (CAT) to Buy... Full story

Yahoo Finance • 2 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of the PIONEER trial; on track to prov... Full story

Yahoo Finance • 2 months ago

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with geneti... Full story

Yahoo Finance • 4 months ago

Neogen Corporation (NEOG): A Bull Case Theory

We came across a bullish thesis on Neogen Corporation on Cornerstone Value’s Substack. In this article, we will summarize the bulls’ thesis on NEOG. Neogen Corporation's share was trading at $5.60 as of August 25th. NEOG’s trailing and for... Full story

Yahoo Finance • 4 months ago

Fulcrum Therapeutics to Present at Upcoming Investor Meetings

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with geneti... Full story

Yahoo Finance • 5 months ago

Noteworthy Tuesday Option Activity: PII, FULC, OXY

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Polaris Inc (Symbol: PII), where a total volume of 9,756 contracts has been traded thus far today, a contract volume whic... Full story

Yahoo Finance • 5 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious adverse events (SAEs) ― ― Observed rob... Full story

Yahoo Finance • 5 months ago

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― Evidence of pan-cellular induction of HbF... Full story

Yahoo Finance • 5 months ago

Curious about the stocks that are showing activity after the closing bell on Monday?

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. [postmarket] AFTER HOURS GAINERS TICKER CHANGE... Full story

Yahoo Finance • 5 months ago

Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically... Full story

Yahoo Finance • 6 months ago

Notable Tuesday Option Activity: FULC, BYON, TGT

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Fulcrum Therapeutics Inc (Symbol: FULC), where a total volume of 2,709 contracts has been traded thus far today, a contra... Full story

Yahoo Finance • 6 months ago

Fulcrum stock maintains Overweight rating at Cantor on sickle cell drug

Investing.com - Cantor Fitzgerald maintained its Overweight rating and $10.00 price target on Fulcrum Therapeutics (NASDAQ:FULC) stock Wednesday, citing potential upside for the company’s sickle cell disease treatment. The stock, currently... Full story

Yahoo Finance • 7 months ago

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetic... Full story

Yahoo Finance • 10 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025 ― ― Ended 2024 with $241.0 million in cash, cash equivalents, and... Full story

Yahoo Finance • 10 months ago

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with geneti... Full story

Yahoo Finance • 11 months ago

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with geneti... Full story